Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...

The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...

The American Diabetes Association has released the Standards of Care in Diabetes-2025, the authoritative guide for ...

Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold ...

The ADA also recommended that if Ozempic and Wegovy are unavailable ... especially as shortages of branded GLP-1 drugs continue.

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed ...